BioWorld

Dec. 23, 2004

Neurochem Signs Potential $54M Deal With Centocor For Fibrillex

Just a few weeks after completing the treatment portion of a Phase II/III trial of Fibrillex, Neurochem Inc. partnered its AA amyloidosis drug with Centocor Inc. in a deal worth up to $54 million. (BioWorld Today) Read More

Isis Sells Macugen Royalties: $24M To Push Pipeline Drugs

Symbollon Beginning Phase III With Product For Breast Pain

Creative Thinking Required For Debate Over Follow-On Biologics

Correction

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Dec. 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 11, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Flow Neuro wins FDA nod for at-home device for depression

BioWorld MedTech

Flow Neuroscience AB received U.S. FDA 510(k) approval for its Flow at-home brain-stimulation device to treat major depressive disorder. The wearable headset uses...

Illustration of leg anatomy with target around knee

Lilly’s retatrutide shows solid weight loss, reduced knee pain

BioWorld

Eli Lilly and Co.’s latest phase III results for the obesity and overweight populations suggest its triple agonist, retatrutide, can deliver significant weight...